MAM
Avon India announces the launch of AVON Lingerie Wear in India
MUMBAI: AVON, the leading direct selling beauty brand enters the realm of fashion with the announcement of AVON Lingerie in India, available from September 2019. With 30 years of innerwear heritage, and as an established lingerie player in the Asia Pacific the region, AVON’s Indian lineup is powered with Invisilite Technology that offers soft, stretchable and seamless products for the ultimate comfort. The AVON Lingerie will have two ranges Body Illusion and Shapemakers Plus promising to deliver the Brand’s standards of superior comfort and fit for all sizes, especially for Asian body types, with fine quality fabrics from across the world.
“Over the years AVON has become a trusted beauty brand in India. Delivering the best products to the consumers in the beauty category, we are delighted to extend our domain and launch lingerie wear in India. The range focuses on technology that makes innerwear feel like a second skin with superior comfort. This will help our brand to stand out in the Indian market and cater to the growing needs of the consumers who are looking for functionality in high fashion lingerie,” said Swati Jain, Marketing Director, AVON India
AVON Lingerie will be focusing on international trends, in terms of exclusive design, color and silhouettes.
The Body Illusion range is a premium brand for AVON that is high on fashion and technology offering a seamless fit for women, with 5 key innovation call-outs: Seamless, Ultra-Stretchable, Breathable, Light & Ultra-Soft. It is armed with a wide variety of silhouettes and sizes to cater to different consumer needs – bras available in sizes from 32A to 40B. The smooth and high stretch fabric makes it an ideal choice for office going women. The range is powered by Invisilite technology for freedom of movement and a buttery soft feel which is exceptionally comfortable, along with a seamless finish that practically renders the innerwear invisible even under skin-tight clothes. The Invisilite fabric fits like a second-skin that provides a sleek silhouette with any outfit.
Avon Shapemakers Plus is the intimate apparel brand created for full-figured women who seek fashion and function, extra support or shape definition in their underwear. The sizes range across a broad spectrum, with 8 sizes from 34B and going up to 42D. The range ensures that the fabrics and materials are carefully chosen to be able to cater for these extra functions without compromising on comfort and fit. The product portfolio also includes Back Smoothing Bra with a broad back and side flaps, and Lifting Bra in Lace with a broader U-shaped back for better support.
According to market analysis by Technopak, the current market size of the intimate wear market is Rs 27,931 crore which is estimated to grow at a CAGR of 10% over the next decade. AVON has shown its presence in more than 50 countries and is a leading brand in the Philippines. Now, India has become the next big lingerie destination for the brand. Avon Body Illusion and Shapemakers Plus range will be available across India through AVON Beauty Representatives starting at Rs 699 and Rs 1299 respectively.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
